Loading clinical trials...

Topical Cannabidiol Application and Skin Vascular Reactivity | Clinical Trials | Clareo Health

WITHDRAWNNA

Topical Cannabidiol Application and Skin Vascular Reactivity

Cannabidiol and Vascular Reactivity to Skin Sensory Nerve Stimulation

NCT05456113•Penn State University

Summary

Cannabidiol, or CBD, is an over-the-counter "nutraceutical" that is more commonly being used by healthy adults for pain management, recovery from strenuous exercise, and general wellness. However, little research exists on the effects of CBD in otherwise healthy individuals. This study uses iontophoresis, a common technique used in physical therapy, to determine the effectiveness of topical CBD in lessening the reflex increased cutaneous vascular conductance response to stimulation of the skin.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Men and women 18 years of age and older
•English speaking
•Non-obese class III, BMI ≤ 39.9
•Normal HbA1C of \<6.5%

Exclusion Criteria

•Abnormal resting heart rate (\<60 or \>100 bpm) or BP (systolic \<100 or \>129 mmHg, diastolic \<60 or \>100 mmHg) values
•Rash, skin disease, disorders of pigmentation
•Known skin allergies
•Diabetes
•Nicotine use (e.g. smoking, chewing tobacco, vaping, etc.)
•Illegal drug use
•Recent (within the last 30 days) CBD users either topical or oral
•Allergy or hypersensitivity to investigational agents
•Women who are pregnant or breastfeeding

Locations (1)

Noll Laboratory

University Park, Pennsylvania, United States

Key Dates

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Completion Date

October 1, 2026

Last Updated

January 17, 2025

Conditions

Effect of Drug

Interventions

Cannabidiol

BIOLOGICAL

Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients

NCT06479655

Effect of Drug

View study

COMPLETEDPHASE2/PHASE3

Growth Hormone in Decompensated Liver Cirrhosis

NCT05253287

Liver CirrhosisFibrosis+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Topical Cannabidiol Application and Skin Vascular Reactivity

Inclusion Criteria

Exclusion Criteria

Compare the Efficacy and Outcome Between Fentanyl and Morphine as Analgo-sedation in Mechanically Ventilated Patients

Growth Hormone in Decompensated Liver Cirrhosis

Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease

Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers